Now Accepting Cases Involving Ozempic, Wegovy, Semaglutide & Similar Drugs
Have you or a loved one experienced vision problems or vision loss after taking
Ozempic, Wegovy, or other weight-loss medications?
The Law Office of Michael Green is actively investigating claims involving
GLP-1 medications are linked to serious and potentially irreversible side effects,
including blindness.
CLICK HERE TO FILL OUT OUR CONTACT
FORM TO GET STARTED TODAY
The Rise of Weight-Loss Drugs Like Ozempic & Wegovy
Originally developed to treat type 2 diabetes, drugs like Ozempic (approved in 2017 by Novo Nordisk) quickly gained popularity after patients experienced unexpected weight loss. This led to the launch of Wegovy, a higher-dose version of Ozempic specifically marketed for weight management.
Today, these medications and others like Rybelsus, Mounjaro, and Zepbound are widely prescribed for both diabetes and weight loss. They all work by mimicking or enhancing a hormone in the body known as GLP-1, which helps control blood sugar and suppress appetite.
How GLP-1 Drugs Work
GLP-1 (Glucagon-like Peptide 1) is a hormone naturally produced in the gut that plays a key role in digestion and metabolism. GLP-1:
Stimulates insulin production, helping lower blood sugar levels
Suppresses glucagon (a hormone that raises blood sugar)
Slows digestion, keeping you fuller longer, and reducing appetite
Medications like Ozempic and Wegovy mimic or enhance the effects of GLP-1, leading to improved blood sugar control and significant weight loss.
Newer drugs such as Mounjaro go a step
further by also activating GIP, another
hormone involved in metabolic control.
Active Ingredients of Concern
Several drugs now on the market use GLP-1 receptor agonists or similar compounds to achieve weight loss effects. These include:
Semaglutide – The active ingredient in Ozempic, Wegovy, and Rybelsus. Mimics GLP-1 to lower blood sugar and suppress appetite.
Tirzepatide – Found in Mounjaro and Zepbound (manufactured by Eli Lilly). Acts on both GLP-1 and GIP pathways, with similar effects.
While these medications have helped many patients manage weight and diabetes, new medical reports have linked them to severe,
life-altering complications.
Serious Side Effects Linked to GLP-1 Drugs
⚠️ Vision Loss
Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
NAION is a rare but serious condition characterized by sudden vision loss, often in
One eye, resulting from reduced blood flow to the optic nerve.
There is no known cure. Recent findings suggest that patients taking semaglutide, especially those with diabetes or obesity—
may face an increased risk of developing NAION compared to those on non-GLP-1 drugs.
⚠️ Intestinal Blockages
In 2023, the FDA received multiple safety
Reports indicating that GLP-1 medications may increase the risk of intestinal obstruction,
a painful and potentially life-threatening condition that often requires surgery.
Symptoms include:
Severe abdominal cramping
Vomiting and nausea
Constipation or inability to pass gas
Bloating or swelling
⚠️ Stomach Paralysis (Gastroparesis)
GLP-1 drugs may also contribute to gastroparesis, a condition where the stomach
cannot empty properly due to nerve or
muscle dysfunction.
Symptoms may include:
Persistent nausea or vomiting
Early satiety (feeling full quickly)
Indigestion, bloating, and upper abdominal pain
Malnutrition and unintended weight loss
You May Be Entitled to Compensation
If you’ve experienced vision loss, gastrointestinal injury, or other severe side effects after taking Ozempic, Wegovy, Mounjaro,
or related medications, we may be able to help. Our legal team is now reviewing claims on behalf of individuals harmed by these drugs.
The Law Office of Michael Green offers compassionate and aggressive representation for clients facing life-altering medical conditions.
Let us fight for your justice. You pay nothing unless we win your case.